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Objectives. Obesity and related diseases are dramatically increasing problems, particularly in children and adolescents. We
determined circulating levels of diﬀerent interleukin (IL)-1 family members in normal weight and overweight adolescents.
Methods. Seventy male, Caucasian adolescents (13–17 years) were recruited. Thirty-ﬁve had a body-mass index (BMI) above
the 90th age-speciﬁc percentile. IL-1α,I L - 1 β, IL-1 receptor antagonist (IL-1ra), and IL-18 were determined using multiplex-
technology. Results. IL-18 concentrations were higher in the overweight group compared to normal weight (161.6 ± 40.7pg/ml
versus134.7±43.4pg/ml,P = .009).ConcentrationsofcirculatingIL-1βlevelswerebelowthedetectionthreshold.IL-18(R2:0.355,
P<. 01) and IL-1ra (R2:0.287, P<. 05) correlated with BMI, whereas IL-1α did not. Conclusions. Accumulating data indicate the
importance of the endocrine function of adipose tissue for the pathophysiological consequences of obesity-related co-morbidities.
SinceIL-18isinvolvedinthepathogenesisofdiﬀerentcardiovasculardiseases,weconcludethatIL-18mayrepresentalinkbetween
obesity and related co-morbidities in children and adolescents.
1.Introduction
Overweight and the related metabolic syndrome are dra-
matically increasing problems, particularly in children and
adolescents [1, 2].
Being overweight in early life signiﬁcantly increases
the risk for and severity of obesity in adulthood [3].
Obesity increases the risk for related morbidities such
as the metabolic syndrome (MS), which is deﬁned as a
clustering of cardiovascular risk factors, including impaired
glucose tolerance, dyslipidemia, and hypertension. Obesity,
especially abdominal obesity, is a hallmark of the MS and
insulin resistance, a consequence of abdominal obesity. In
addition, abdominal obesity is considered to be the driving
forceoftheMS.Furthermore,type2diabetesmellitus(T2D)
now accounts for up to 45 percent of all newly diagnosed
diabetes in pediatric patients in northern America [4].
In the last decade, increasing evidence suggested the
striking relevance of a low but chronic inﬂammatory state
in obesity and MS. Population-based studies have shown
strong relationship between inﬂammatory markers and lipid
metabolism abnormalities, obesity, and resulting complica-
tions such as atherosclerosis [5, 6]. This presence of chronic
low-grade inﬂammation in obese states, in insulin resistance,
the MS, and T2D, and in early stages of atherogenesis
supportsthenotionthatinﬂammationmaybethecausallink
connecting adipose tissue dysfunction with metabolic and
vascular pathologies [7]. Research of recent years revealed
a role of adipose tissue beyond energy storage harboring
inﬂammatory cells which are believed to sustain inﬂamma-
tion and impair adipocyte function [8]. These eﬀects might
be mediated by cytokines released in substantial amounts
from adipocytes, as well as from inﬂammatory cells recruited
into adipose tissue. Many proinﬂammatory cytokines such
as tumor necrosis factor alpha (TNFα) and interleukin
(IL)-6, as well as other markers like leptin, adiponectin,
and stromal-derived-factor (SDF) 1 in overweight children
and adolescents have attracted considerable attention [9–
13]. In addition, cytokines of the IL-1 family have been
described to be elevated in overweight adults. This family2 Mediators of Inﬂammation
includes among others IL-1α, IL-1 receptor antagonist (IL-
1ra), IL-1β, and IL-18. Both proinﬂammatory cytokines,
IL-1β and IL18, are elevated in adult obesity and share a
similar signal transduction pathway [14] .T h eI L - 1 r ai sa n
anti-inﬂammatory cytokine that is also produced by white
adipose tissue. IL-1ra binds to the IL-1 receptor in a non-
activating fashion competing with and antagonizing the
proinﬂammatory IL-1 [15]. Systemic levels of IL-1ra were
shown to be elevated in obese adults likely representing a
protective response to the rise of IL-1 [16].
The aim of this study was to investigate circulating levels
of IL-1 family cytokines in adolescents and the inﬂuence of
obesity in early life as well as the correlation to markers of
glucose metabolism (adiponectin) and endothelial damage.
2. Methods
2.1. Study Subjects. Voluntary individuals were recruited
in schools of the region of Jena, Germany. Seventy male,
Caucasian adolescents (aged 13–17 years) were studied. Of
these 35 (50%) had a body-mass index (BMI) above the
90th percentile according to German charts [17]. Subjects
and their parents gave informed consent and protocols were
approved by the University’s ethics committee in accordance
with the Helsinki Declaration II.
For all participants the following parameters were
recorded in one consultation: age, height, weight, waist
and hip circumference, heart rate, and blood pressure
(systolic and diastolic). Any sign of disease was an exclu-
sion criterion. BMI was calculated with the formula:
body weight[kg]/height[cm]
2. BMI-standard deviation score
(SDS) was calculated according to current guidelines
using German charts [17]. Brieﬂy, the formula BMI-SDS=
([BMI/M(t)]
L(t)–1)/L(t)∗S(t) was used. M(t) is the age- and
sex-speciﬁc BMI median. L(t) and S(t) are age and sex-
speciﬁc calculation variables available in charts.
2.2. Routine Laboratory. Blood samples were drawn in the
morning after an overnight fast using EDTA as anticoagu-
lant. Standard plasma parameters were obtained from the
Department of Clinical Chemistry at the University Hospital
Jena: high-density lipoprotein (HDL; mmol/l), low-density
lipoprotein (LDL; mmol/l), triglycerides (mmol/l), and C-
reactiveprotein(CRP,mg/l;usinghighsensitivityassay)were
analyzed.
2.3. Cytokine Determination. The quantitative determina-
tionofhumanIL-1α,IL-1β,IL-1ra,andIL-18wasperformed
using immediately frozen plasma (−70
◦C). Cytokines were
determined by Bio-Plex technology according to the man-
ufacturer’s instructions (Bio-Rad, Hercules, CA). Brieﬂy,
ﬂuorescently-dyed microspheres coated with a capture anti-
body bind to relevant cytokines in a sandwich immuno-
assay format. Following removal of unbound sample speciﬁc
protein was detected with a ﬂuorescently labeled antibody
and analyzed in a Luminex analyzer [18].
2.4. ELISA. As surrogate markers for insulin sensitivity and
glucose metabolism [19] and for early endothelial damage
[20] and activation, adiponectin and soluble E-selectin (sE-
selectin),respectively, were measured using ELISA technique
according to manufacturer’s instructions (R&D Systems,
Wiesbaden, Germany).
2.5. Statistical Analysis. Cytokine levels between groups were
compared with t-test. Correlation analyses between cytokine
levels and other laboratory values or patient characteristics
employed Pearson correlation coeﬃcient. For correlation
between cytokines and the ELISA markers, linear regression
analysis was also used. Statistical signiﬁcance was assumed if
a null hypothesis could be rejected at P ≤ .05. All statistical
analyses were performed with SPSS, version 12.0 (SPSS Inc.).
3. Results
ThebaselinecharacteristicsareshowninTable 1.Overweight
adolescents had higher BMI, BMI-SDS, waist circumference,
and systolic blood pressure at rest. Levels of triglycerides,
total cholesterol, and LDL did not diﬀer, but HDL was
lower in overweight adolescents. In addition, overweight
adolescents had higher levels of CRP likely reﬂecting a low-
grade inﬂammatory state.
Concentrations of circulating IL-1β levels were
below the detection threshold. IL-1α (normal weight:
29.40±7.81pg/mL versus overweight: 31.62±9.26pg/mL;
P=.281) and IL-1ra (normal weight: 203.79±178.18pg/mL
versus overweight: 280.15±213.37pg/mL; P=.109) levels
did not diﬀer signiﬁcantly, whereas IL-18 was higher
in overweight adolescents (134.73±43.38pg/mL versus
161.57±40.67pg/mL; P=.009).
IL-1ra and IL-18 correlated with all anthropometrical
measurements of obesity, including body weight, BMI,
BMI-SDS, and waist circumference, whereas IL-1α did not
(Table 2) .B l o o dp r e s s u r el e v e l sa tr e s th a dn oa s s o c i a -
tion with any of the investigated cytokines. Triglycerides,
total cholesterol, and LDL cholesterol correlated with IL-
1α, whereas HDL cholesterol correlated inversely with IL-
18. Higher inﬂammatory state determined by CRP was
associated with higher IL-1α and IL-18. To further dissect
the relevance of IL-1 family cytokines, we correlated (linear
regression analysis) these markers with adiponectin as surro-
gate for beginning insulin resistance and glucose metabolism
and sE-selectin as plasma correlate for functional and
morphological changes in the vessel wall in teenagers. IL-1α,
IL-18, and IL-1ra did not correlate with adiponectin (data
not shown). Correlation of sE-selectin to IL-1ra also did not
show signiﬁcant results, but sE-selectin correlated to IL-1α
and IL-18 (both P<. 001, Figure 1).
4. Discussion
During the past decades, the industrialized countries wit-
nessed a dramatic increase in the prevalence of obesity.
Recent research has clearly conﬁrmed that overweight and
especially obesity are associated with a chronic subclinicalMediators of Inﬂammation 3
Table 1: Characteristics of the study population. Data are presented as mean±standard deviation. n.s.: not signiﬁcant.
Normal weight adolescents Overweight adolescents P-value
N3 5 3 5
Age (Years) 15.3 15.1 n.s.
Body Weight (kg) 63.3±7.6 97.0±19.3 <.001
BMI 20.5±1.9 32.1±5.2 <.001
BMI-SDS 0.05±0.68 2.39±0.52 <.001
Waist circumference (cm) 72.7±4.4 100.2±13.5 <.001
Systolic blood pressure (mmHg) 120±11 134±17 .021
Triglycerides (mmol/l) 0.89±0.29 1.12±0.74 n.s.
Total cholesterol (mmol/l) 3.92±0.79 4.09±0.77 n.s.
LDL cholesterol (mmol/l) 2.37±0.82 2.55±0.72 n.s.
HDL cholesterol (mmol/l) 1.27±0.21 1.10±0.22 .002
High-sensitive CRP (mg/dl) 0.52±1.49 2.69±3.19 .001
Table 2 :C o r r e l a t i o no fI L - 1 α, IL-1ra, and IL-18 to anthropometrical measurements of obesity, patient characteristics, and diﬀerent lab
values. Indicated is the Pearson correlation coeﬃcient (R2).
IL-1α IL-1ra IL-18
Body Weight 0.217ns 0.366∗∗ 0.346∗∗
BMI 0.200ns 0.287∗ 0.355∗∗
BMI-SDS 0.198ns 0.284∗ 0.349∗∗
Waist circumference 0.221ns 0.346∗∗ 0.366∗∗
Systolic blood pressure −0.110ns −0.065ns −0.302ns
Triglycerides 0.331∗∗ 0.242∗∗ 0.225ns
Total cholesterol 0.332∗∗ 0.166 0.055
LDL cholesterol 0.333∗∗ 0.120ns 0.202ns
HDL cholesterol −0.152ns −0.194ns −0.239∗
CRP 0.298∗ 0.208ns 0.277∗
ns:not signiﬁcant
∗:signiﬁcant at 0.05 level
∗∗:signiﬁcant at 0.01 level
inﬂammation [21]. Adipose tissue is not merely a simple
reservoir of energy stored as triglycerides, but serves as
an active secretory organ releasing many peptides and
cytokines into the circulation. In the state of obesity, the
balance between these numerous molecules is dysregulated.
Enlargement of adipocytes producing more proinﬂamma-
tory cytokines (i.e. TNFα, IL-6) and less anti-inﬂammatory
proteins, such as adiponectin, was suggested as one potential
explanation[22].Othersproposedthatinﬁltrationofinﬂam-
matory cells may represent the critical step in adipose tissue-
associated inﬂammation, although the initial trigger(s) for
accumulation of these cells remains elusive. The present
study extends the existing knowledge about alterations in the
IL-1 family in obese adults to obese teenagers.
Elevation of IL-1α and IL-1ra has been described under
diﬀerent conditions, including overweight and diabetes,
while circulating levels of IL-1β were reported below the
sensitivity of the assays [23, 24]. Of note, the pathophysi-
ological link between obesity and resulting T2D mediated
by IL-1α,I L - 1 β, and their antagonist IL-1ra is discussed in
current literature, but is not completely understood. While
IL-1α inhibits insulin signaling in adipocytes [25], IL-1β
mediated cytotoxic eﬀects in pancreatic islets consequently
leading to impaired insulin secretion [26]. Therefore, IL-1ra
received considerable clinical attention due to the potential
therapeutic application of this natural inhibitor. Interest-
ingly, treatment with an IL-1 antibody improves glycemic
control in diet-induced obesity in mice [27]. In adolescents
these cytokines—if detectable—did not diﬀer signiﬁcantly
between groups. However, mean numbers in overweight
adolescents showed a trend for IL-1ra to be increased and
IL-1ra correlated with anthropometrical measurements of
obesity, such as waist circumference, which is a good marker
for visceral adipose tissue. This correlation suggests that
the recruitment of this endogenous protective mechanism
already starts in early life controlling activation of the IL-
1 axis. Furthermore, we observed an intriguing association
between IL-1α and sE-selectin. Invitro studies showed that
IL-1α promotes procoagulative activity and inﬂammation in
endothelial cells [28]. Since circulating levels of sE-selectin
reﬂect remarkably well structural and functional changes of
the vessel wall in early life [20], it is tempting to speculate4 Mediators of Inﬂammation
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Figure 1: Association of soluble E-selectin (sE-selectin) with IL-1α
(a) and IL-18 (b). Both correlations: P<. 001.
whether IL-1α is involved into such changes. Future studies
will have to elucidate this question.
IL-18 is closely related to IL-1β sharing structural and
functional similarities. Both the IL-1 receptor and IL-18
receptor belong to the same receptor superfamily [29]. IL-18
isimplicatedinthepathogenesisofseveraldiseasesincluding
atherosclerosisandischemicheartdisease[30–32],andmore
recently a novel function for IL-18 in the control of energy
homeostasis has also been described [33]. Zirlik et al. and
others reported that circulating levels of IL-18 in human
adults directly correlate with BMI, adiposity, and insulin
resistance and are elevated in obesity [31, 34]. In adipose
tissue, resident macrophages are the major source of IL-18
[35], supported by Fain et al., showing that the nonfat cells
in human adipose tissue contribute to most of the release of
IL-18[36].TheseresultshighlighttheimportanceofIL-18in
obesity, furthermore, supported by animal studies showing
that IL-18 modulates food-intake, leading to hyperphagia
in IL-18 deﬁcient mice [37]. In our adolescent cohort,
IL-18 is elevated in overweight individuals and correlates
with diﬀerent anthropometrical measurements of obesity.
Furthermore, it is associated with inﬂammatory state (CRP)
and endothelial damage (sE-selectin), underlining the early
development of atherosclerosis in overweight teenagers and
the connecting role of inﬂammation mediated by factors
such as IL-18. Since insulin resistance is a crucial component
of MS, it is surprising that IL-18 is not associated (inverse)
with adiponectin. However, our data corroborate previous
studies reporting that in obese children and adults, IL-18
levels can be independent of the alterations in adiponectin
[38, 39].
Zilverschoon et al. recently proposed a mechanism of
IL-18 resistance which is of potential relevance for the
understanding of the consequences of high IL-18 levels [40].
In their study obese adults are characterized by higher levels
of IL-18, but their leucocytes show lower response to IL-
18 stimulation. The development of IL-18 resistance may
provide an explanation for the increased susceptibility of
overweight subjects for infections. This hypothesis, which
remains to be tested, may also hold true for children and
adolescents since an increased frequency of infections was
reported for obese or overweight subjects [41]. Thus, future
studies have to address the correlations between IL-18 levels,
obesity, and infections in early life.
We would like to discuss some strengths and weaknesses
of our study: a limitation is that the study cohort is
comparably small. Since IL-1ra correlated well with diﬀerent
anthropometrical measurements of obesity, it is reasonable
to speculate that there might also be a diﬀerence between
groups if group size would be bigger. However, group sizes
were powerful enough to reveal striking diﬀerences for a
related cytokine of the same family. An obvious strength of
this study is that it—to the best of our knowledge—for the
ﬁrst time investigates IL-1 family cytokines in normal weight
and overweight adolescents.
In summary, we conclude that cytokines of IL-1 family
are involved in pathophysiological conditions that occur in
overweight adolescents. Notably, IL-18 is elevated in over-
weightteenagers,correlatingwithdiﬀerentanthropometrical
measurement of obesity and associated with sE-selectin, a
marker for endothelial damage. However, IL-1α and IL-1ra
are not signiﬁcantly elevated and may not contribute to the
pathophysiology that increases the frequency of diabetes in
overweight adolescents. Early changes in cytokine proﬁle
underline the urgency of ﬁghting obesity in childhood and
adolescence.Mediators of Inﬂammation 5
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